299 件 ・ 関連度順
概要と使いどころ
Analyze mental health care planning systems for treatment goal alignment, intervention scheduling, progress milestone tracking, multi-provider coordination, step-down/step-up criteria, and individualized care pathway optimization..
日本語の概要は準備中です。原文の説明を表示しています。
Write a technical tax position memo that documents a tax filing position with authorities, facts, analysis, and conclusion. Use when a tax professional says "write a tax memo", "document this tax position", "research memo for the partner", "we need to support this deduction", "document the tax treatment", "write up the authority for this position", "technical memo on [tax issue]", "MLTN analysis", "reasonable basis memo", "document the IRC section that supports this", or needs to formally document a tax conclusion. Also trigger when someone has a tax question that needs a written conclusion backed by legal authority - even if they don't use the words "tax memo" or "tax position".
日本語の概要は準備中です。原文の説明を表示しています。
Audit and fix agent readiness: the Lighthouse Agentic Browsing fraction, accessibility tree for agents, robots.txt and Content-Signal for AI agents, WAF treatment of agent traffic, llms.txt, Markdown delivery, ai-catalog.json, /.well-known discovery files, and WebMCP tools. Exclude AI citability and brand signals (seo-geo) and commerce protocol depth (seo-ecommerce).
日本語の概要は準備中です。原文の説明を表示しています。
ผู้ช่วยทันตแพทย์ — dental code reference + treatment planning + materia medica dental + clinical pearl สำหรับทันตแพทย์ที่มีใบประกอบวิชาชีพเท่านั้น
日本語の概要は準備中です。原文の説明を表示しています。
Design and build cohesive web pages with custom visual identity — landing pages and portfolios get rich anatomy + section archetypes; any other page type (blog, about, pricing, contact, coming-soon, dashboard, admin, e-commerce, custom) is supported through generic anatomy + skeleton. Use this skill whenever the user mentions: landing page, portfolio, personal site, hero section, marketing page, product page, sales page, splash page, blog page, about page, pricing page, contact page, coming-soon, waitlist, dashboard, admin panel, e-commerce store, redesign my site, design my portfolio, build a portfolio, work showcase, hire-me page, perfect-ui, perfect landing, or asks to create any web page surface. Two tiers: special (landing | portfolio — rich treatment) and generic (everything else — universal craft toolkit). Self-contained 8-phase pipeline: vibe discovery → visual direction (color/typography/mood) → custom icon set (NO emoji, NO icon library) → AI-generated visuals → optional shader effects layer → inline plan + implement on Next.js + Tailwind + shadcn. Always proposes effect layer as optional. No refusals; outputs distinctive sites, not AI slop.
日本語の概要は準備中です。原文の説明を表示しています。
This skill should be used when the user asks to "implement a DiD regression", "run a staggered difference-in-differences", "set up an event study", "implement IV / 2SLS", "run a regression discontinuity design", "build synthetic control", "do propensity score matching", "test parallel trends", "run Honest DiD", "wild cluster bootstrap", "Callaway-Sant'Anna", "Sun-Abraham", "Bacon decomposition", "double machine learning", "debiased machine learning", "DML / DoubleML", "cross-fitting", "causal forest", "heterogeneous treatment effects", "ATE with ML controls", "which causal design fits my data", or needs causal-inference code, diagnostics, or identification writing in Python (StatsPAI), R, or Stata. Based on Scott Cunningham's Causal Inference: The Mixtape, with runnable validated templates, ML-based causal inference patterns, and Journal of Finance applications.
日本語の概要は準備中です。原文の説明を表示しています。
Apply GEODE's measured architecture, module and symbol naming, Python type/class, persisted schema, test, site, and versioning conventions. Use when adding or moving modules, choosing dataclass/Pydantic/Protocol/ABC forms, naming classes or files, designing stored data, reviewing convention compliance, or deciding compatibility and release version treatment.
日本語の概要は準備中です。原文の説明を表示しています。
Drafts USMCA/NAFTA Certificates of Origin for preferential tariff treatment on US-Mexico-Canada goods. Verifies origin criteria, HS classifications, and regional value content. Use when preparing trade certificates, customs origin documentation, duty preference claims, or cross-border shipment certifications.
日本語の概要は準備中です。原文の説明を表示しています。
Drafts a Chapter 11 Plan of Reorganization under 11 U.S.C. §§ 1121–1129 with claim classification, treatment provisions, distribution mechanics, executory contract determinations, and confirmation compliance. Use when preparing reorganization plans, restructuring debts, classifying claims, drafting Chapter 11 plans, or helping debtors emerge from bankruptcy. Trigger keywords: reorganization plan, Chapter 11, plan of reorganization, debt restructuring, cramdown, claim classification, confirmation order.
日本語の概要は準備中です。原文の説明を表示しています。
Implement randomization methods for RCTs. Use when user mentions: random assignment, treatment allocation, stratification, blocking, permutation randomization, cluster randomization, randomization balance, misfit handling, re-randomization.
日本語の概要は準備中です。原文の説明を表示しています。
Analyze data from randomized controlled trials. Use when user mentions: treatment effects, ITT analysis, LATE, TOT, compliance analysis, attrition, balance checks, heterogeneous effects, RCT results, experimental analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Design randomized controlled trials for causal inference. Use when user mentions: randomized evaluation, RCT, field experiment, randomized experiment, treatment assignment, causal impact, experimental design, control group, intervention evaluation.
日本語の概要は準備中です。原文の説明を表示しています。
Designs the first screen visitors see — the hero section. Layout patterns (split, centered, asymmetric, full-bleed), navbar design, headline typography, CTAs, background treatments (gradients, video, particles, 3D), scroll cues, and above-the-fold conversion strategy. Activate on 'hero section', 'landing page hero', 'above the fold', 'first impression', 'homepage header', 'navbar design', 'hero layout', 'landing page design'. NOT for full multi-page site architecture (use web-design-expert), not for SEO content strategy (use seo-visibility-expert).
日本語の概要は準備中です。原文の説明を表示しています。
Identify and counteract cognitive biases in medical decision-making through systematic error analysis and contextual algorithm application. For diagnostic reasoning, treatment decisions, and clinical judgment improvement. NOT for basic medical knowledge, technical procedures, or non-clinical healthcare domains.
日本語の概要は準備中です。原文の説明を表示しています。
Expert in cluttering -- the lesser-known fluency disorder characterized by rapid/irregular speech rate, excessive disfluencies, and frequent ADHD comorbidity. Covers differential diagnosis from stuttering, assessment protocols, therapy approaches (rate control, self-monitoring, pragmatic awareness), technology-assisted intervention, and AI tools for people who clutter. Activate on 'cluttering', 'rapid speech disorder', 'speech rate too fast', 'speech disfluency not stuttering', 'disorganized speech', 'ADHD speech problems', 'cluttering vs stuttering', 'speech intelligibility', 'mazed speech', 'telescoping words'. NOT for stuttering-only treatment (overlap is common but they are distinct), hearing disorders, or voice disorders (pitch, resonance).
日本語の概要は準備中です。原文の説明を表示しています。
Identifies differential m6A methylation between conditions from MeRIP-seq paired IP/input data using exomePeak2 (GC-bias-aware differential via its bam_ip/bam_input control + bam_treated_ip/bam_treated_input treatment arms), QNB beta-binomial, MeTDiff HMM, and RADAR, plus the paired-symmetric edgeR/DESeq2-on-peak-counts route when batch/lot covariates need fixed-effect handling that exomePeak2's API does not accept. Covers paired vs unpaired vs interaction designs, batch confounding and per-lot meta-analysis, the stoichiometry-vs-expression-vs-IP-efficiency confound, and effect-size filtering against under-powered N=2 designs. Use when comparing m6A across two or more conditions, choosing between exomePeak2/QNB/RADAR/MeTDiff for a design, handling batch confounding when exomePeak2's API is too rigid, distinguishing real hyper/hypo-methylation from expression shifts, applying effect-size thresholds, or planning orthogonal stoichiometry validation (GLORI/SAC-seq/m6Anet mod_ratio).
日本語の概要は準備中です。原文の説明を表示しています。
Compare gene co-expression and regulatory networks between biological conditions to find rewired relationships using DiffCorr, DiffCoEx, DINGO/iDINGO, and CoDiNA. Covers the differential-connectivity-is-not-differential-expression distinction, the pairwise multiple-testing explosion, marginal vs partial (direct) rewiring, and the underpowered-rewiring failure mode. Use when comparing co-expression networks between disease vs control, treatment, or developmental stages, or finding hub genes that rewire without changing mean expression. For single-condition modules see coexpression-networks; for differential expression of means see differential-expression/de-results.
日本語の概要は準備中です。原文の説明を表示しています。
Detects differential alternative splicing between conditions using rMATS-turbo (binomial LRT on junction counts), leafcutter (Dirichlet-multinomial GLM on intron clusters), MAJIQ V3 deltapsi/HET (Bayesian posterior on LSVs), SUPPA2 (empirical-null on TPM-derived PSI), or Shiba (junction-imbalance-corrected, 2025 SOTA at low coverage). Reports FDR-corrected significance and delta PSI effect sizes. Tools differ in statistical model, annotation dependence, calibration regime, and replicate-count requirements. Use when comparing splicing patterns between treatment groups, tissues, or disease states.
日本語の概要は準備中です。原文の説明を表示しています。
Identify differentially bound regions across CLIP-seq conditions (knockdown vs control, treatment vs vehicle, disease vs healthy) using DEWSeq (sliding-window DESeq2), Flipper (Skipper-downstream), ASpeak, edgeR, or limma-voom. Use when computing condition-level changes in RBP binding intensity, choosing peak-level vs window-level vs crosslink-level testing, designing replicate experiments, or distinguishing biological binding shifts from technical confounders.
日本語の概要は準備中です。原文の説明を表示しています。
Reads, validates, and prepares CDISC SDTM and ADaM clinical trial data for analysis. Covers SDTM domain joins (DM, AE, EX, VS, LB, DS), ADaM architecture (ADSL, BDS, OCCDS, ADTTE) with traceability, treatment-emergent AE conventions, baseline derivation, SUPPQUAL/NSV handling, Define-XML 2.1, and Pinnacle 21 / CORE validation. Use when working with clinical trial datasets in CDISC SDTM/ADaM format, preparing analysis-ready data, or validating for regulatory submission.
日本語の概要は準備中です。原文の説明を表示しています。
Tests associations between categorical variables in clinical data using chi-square, Fisher's exact, Boschloo, Cochran-Mantel-Haenszel, and modern McNemar variants with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen). Use when analyzing categorical outcomes, paired binary endpoints, or testing treatment-outcome independence in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Decompose total effects into direct and indirect paths through mediators using mediation, CMAverse 4-way, HIMA/HIMA2 high-dimensional, BAMA, two-step / MVMR mediation, or double-ML medDML. Use when testing whether a molecular phenotype (expression, methylation, protein) mediates a treatment-outcome relationship, decomposing exposure-mediator interaction via VanderWeele 4-way, screening high-dimensional EWAS mediators, or running MR-based mediation when sequential ignorability is implausible.
日本語の概要は準備中です。原文の説明を表示しています。
Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.
日本語の概要は準備中です。原文の説明を表示しています。
Identify differentially accessible chromatin regions across conditions using DiffBind, csaw, DESeq2, or edgeR. Use when comparing ATAC-seq accessibility between treatment groups, choosing between consensus-peak vs sliding-window approaches, picking the correct normalization (full library vs reads-in-peaks), correcting batch with SVA/RUVseq, or interpreting log2FC and FDR thresholds in a chromatin context.
日本語の概要は準備中です。原文の説明を表示しています。